Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Conditions
IgA Nephropathy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Univ of Alabama/Birmingham, Birmingham, Alabama, United States
Contact: Study coordinator (Principal Investigator)Arizona Kidney Disease & Hypertension Centers (AKDHC), Glendale, Arizona, United States
Contact: Study coordinator (Principal Investigator)The Medical Research Group, Inc., Fresno, California, United States
Contact: Principal Investigator (Harpreet Dhindsa)UCI Health-UCI Medical Center, Orange, California, United States
Contact: Study coordinator (Principal Investigator)Loma Linda University, San Bernardino, California, United States
Contact: Principal Investigator (Sayna Norouzi)UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice, San Francisco, California, United States
PIStanford University, Stanford, California, United States
Contact: Study coordinator (Principal Investigator)University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location, Aurora, Colorado, United States
Contact: Study coordinator (Principal Investigator)Yale University Nephrology Clinical Trials Program, New Haven, Connecticut, United States
Contact: Study coordinator (Principal Investigator)Florida Kidney Physicians, Boca Raton, Florida, United States
Contact: Study coordinator (Principal Investigator)Central Florida Kidney Specialists, Orlando, Florida, United States
Contact: Study coordinator (Principal Investigator)Southeastern Clinical Research Institute, LLC, Augusta, Georgia, United States
Contact: Study coordinator (Principal Investigator)Cobb Nephrology Hypertension Associates, PC, Austell, Georgia, United States
Contact: Study coordinator (Principal Investigator)Georgia Nephrology, Lawrenceville, Georgia, United States
Contact: Principal Investigator (James Tumlin)University of Louisville, Louisville, Kentucky, United States
Contact: Principal Investigator (Gunjan Garg)Ochsner Health, New Orleans, New Orleans, Louisiana, United States
Contact: Study coordinator (Principal Investigator)University of Maryland Division of Nephrology, Baltimore, Maryland, United States
Contact: Principal Investigator (Preeti Chandra)Boston Medical Center; Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
Contact: Principal Investigator (Ashish Upadhyay)University of Minnesota Health Fairview, Minneapolis, Minnesota, United States
Contact: Principal Investigator (Nattawat Klomjit)Washington University in St. Louis, St Louis, Missouri, United States
Contact: Study coordinator (Principal Investigator)University of New Mexico, Albuquerque, New Mexico, United States
Contact: Study coordinator (Principal Investigator)Renal Medical Associates, Albuquerque, New Mexico, United States
Contact: Study coordinator (Principal Investigator)New York Nephrology Vasculitis and Glomerular Center, Clifton Park, New York, United States
Contact: Principal Investigator (Frank Cortazar)Chinatown Kidney Care, PLLC, New York, New York, United States
Contact: Study coordinator (Principal Investigator)Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Study coordinator (Principal Investigator)North Carolina Nephrology, P.A, Raleigh, North Carolina, United States
Contact: Principal Investigator (Michael Casey)Ohio State University, Columbus, Ohio, United States
Contact: Study coordinator (Principal Investigator)Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic, Portland, Oregon, United States
Contact: Study coordinator (Principal Investigator)University of Pennsylvania Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Principal Investigator)Dallas Renal Group, Dallas, Texas, United States
Contact: Study coordinator (Principal Investigator)MedResearch Inc, El Paso, Texas, United States
Contact: Study coordinator (Principal Investigator)The University of Texas Medical Branch UTMB, Galveston, Texas, United States
Contact: Study coordinator (Principal Investigator)Memorial Hermann Houston, Houston, Texas, United States
Contact: Study coordinator (Principal Investigator)Prolato Clinical Research Center, Houston, Texas, United States
Contact: Study coordinator (Principal Investigator)The Kidney Institute/Houston, Houston, Texas, United States
Contact: Study coordinator (Principal Investigator)Dallas Nephrology Associates McKinney, McKinney, Texas, United States
Contact: Study coordinator (Principal Investigator)Permian Basin Kidney Center, Odessa, Texas, United States
Contact: Study coordinator (Principal Investigator)Advanced Renal Care Institute, Mayagüez, Puerto Rico
Contact: Study coordinator (Principal Investigator)
Study leads
Krassimir Mitchev
Study Director
Calliditas Therapeutics